The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system

Pathogen Recognition and Innate Immunity

Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 11,974 · see citing works

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304 · see citing works

A Toll-like receptor recognizes bacterial DNA

Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · see citing works

Drug Delivery Systems: Entering the Mainstream

Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552 · see citing works

Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8

Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947 · see citing works

The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5

Hayashi, F., Smith, K. D., Ozinsky, A., Hawn, T. R., Yi, E. C., Goodlett, D. R., Eng, J. K., Akira, S., Underhill, D. M., & Aderem, A. A. (2001) · Nature · doi:10.1038/35074106 · Cited by 3,605 · see citing works

The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect

Fang, J. Q., Nakamura, H., & Maeda, H. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,573 · see citing works

Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA

Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444 · see citing works

Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway

Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., & Akira, S. (2002) · Nature Immunology · doi:10.1038/ni758 · Cited by 2,517 · see citing works

Recognition of single-stranded RNA viruses by Toll-like receptor 7

Lund, J. M., Alexopoulou, L., Sato, A., Karow, M. L., Adams, N. C., Gale, N. W., Iwasaki, A., & Flavell, R. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400937101 · Cited by 1,854 · see citing works

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Harper, D. M., Franco, E. L., Wheeler, C. M., Moscicki, A., Romanowski, B., Roteli-Martins, C. M., Jenkins, D., Schuind, A., Clemens, S. A. C., & Dubin, G. O. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68439-0 · Cited by 1,629 · see citing works

Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7

Hornung, V., Guenthner‐Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A. M., Manoharan, M., Akira, S., de Fougerolles, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1191 · Cited by 1,233 · see citing works

Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists

Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869 · see citing works

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909

Speiser, D. E., Líénard, D., Rufer, N., Rubio‐Godoy, V., Rimoldi, D., Lejeune, F. J., Krieg, A. Μ., Cerottini, J., & Romero, P. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23373 · Cited by 637 · see citing works

CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells

Hartmann, G., Weiner, G. J., & KRIEG, A. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9305 · Cited by 617 · see citing works

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies

Geisse, J. K., Caro, I., Lindholm, J. S., et al. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.11.066 · Cited by 508 · see citing works

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

Brody, J., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M. A., Advani, R. H., Kim, Y. H., Hoppe, R. T., Knox, S. J., Shin, L. K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9793 · Cited by 489 · see citing works

Toll-Like Receptor Signaling Inhibits Hepatitis B Virus Replication In Vivo

Isogawa, M., Robek, M. D., Furuichi, Y., & Chisari, F. V. (2005) · Journal of Virology · doi:10.1128/jvi.79.11.7269-7272.2005 · Cited by 443 · see citing works

Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer

Butts, C. A., Murray, N., Maksymiuk, A. W., Goss, G. D., Marshall, E., Soulières, D., Cormier, Y. F., Ellis, P., Price, A., Sawhney, R. P. S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.011 · Cited by 427 · see citing works

Paternal DNA packaging in spermatozoa: more than the sum of its parts? DNA, histones, protamines and epigenetics

Miller, D., Brinkworth, M. H., & Iles, D. (2009) · Reproduction · doi:10.1530/rep-09-0281 · Cited by 416 · see citing works

Treatment of Vulvar Intraepithelial Neoplasia with Topical Imiquimod

van Seters, M., van Beurden, M., ten Kate, F. J. W., Beckmann, I., Ewing, P. C., Eijkemans, M. J. C., Kagie, M. J., Meijer, C. J. L. M., Aaronson, N. K., KleinJan, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa072685 · Cited by 392 · see citing works

TLR9 as a key receptor for the recognition of DNA☆

Kumagai, Y., Takeuchi, O., & Akira, S. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.12.004 · Cited by 389 · see citing works

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer

KRIEG, A. M. (2008) · Oncogene · doi:10.1038/sj.onc.1210911 · Cited by 389 · see citing works

Triggering TLR signaling in vaccination

van Duin, D., Medzhitov, R. M., & Shaw, A. C. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.11.005 · Cited by 364 · see citing works

TLR7 and TLR8 as targets in cancer therapy

Schön, M., & Schön, M. (2008) · Oncogene · doi:10.1038/sj.onc.1210913 · Cited by 302 · see citing works

Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial.

Herr, H. W., Schwalb, D. M., Zhang, Z., Sogani, P. C., Fair, W. R., Whitmore, W. F., & Oettgen, H. F. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.6.1404 · Cited by 300 · see citing works

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming

Valmori, D., Souleimanian, N. E., Tosello, V., Bhardwaj, N., Adams, S., O’Neill, D. W., Pavlick, A. C., Escalon, J., Cruz, C. M., Angiulli, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703395104 · Cited by 297 · see citing works

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: A double-blind, randomized, vehicle-controlled study*

Geisse, J. K., Rich, P. A., Pandya, A. G., et al. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.126215 · Cited by 288 · see citing works

Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate.

Sands, H., Gorey‐Feret, L. J., Cocuzza, A. J., Hobbs, F. W., Chidester, D. R., & Trainor, G. L. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10208-3 · Cited by 267 · see citing works

Pharmacokinetics of Antisense Oligonucleotides

Agrawal, S., Temsamani, J., Galbraith, W. M., & Tang, J. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199528010-00002 · Cited by 261 · see citing works

Adjuvants for cancer vaccines

Dubensky, T. W., & Reed, S. G. (2010) · Seminars in Immunology · doi:10.1016/j.smim.2010.04.007 · Cited by 259 · see citing works

Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis

Joyce, J. A., Laakkonen, P., Bernasconi, M., Bergers, G., Ruoslahti, E. I., & Hanahan, D. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00271-x · Cited by 254 · see citing works

Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia

Daayana, S., Elkord, E., Winters, U., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605611 · Cited by 252 · see citing works

Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant

Adams, S., O’Neill, D. W., Nonaka, D., Hardin, E. A., Chiriboga, L. A., Siu, K., Cruz, C. M., Angiulli, A., Angiulli, F., Ritter, E., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.776 · Cited by 247 · see citing works

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe

Schulze, H. J., Cribier, B. J., Requena, L., REIFENBERGER, J., Ferrándiz, C., Díez, A. G., Tebbs, V. M., & McRae, S. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06486.x · Cited by 241 · see citing works

Toll-like receptors as potential therapeutic targets for multiple diseases

Zuany‐Amorim, C., Hastewell, J. G., & Walker, C. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd914 · Cited by 231 · see citing works

Amb a 1–immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response

Tulić, M. K., Fiset, P., Christodoulopoulos, P., Vaillancourt, P., Desrosiers, M. Y., Lavigne, F., Eiden, J., & Hamid, Q. A. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.11.001 · Cited by 231 · see citing works

Use of A‐type CpG oligodeoxynucleotides as an adjuvant in allergen‐specific immunotherapy in humans: a phase I/IIa clinical trial

Senti, G., Johansen, P., Haug, S., Bull, C., Gottschaller, C., Muller, P. H., Pfister, T., Maurer, P., Bachmann, M. F., Graf, N. M., et al. (2009) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2008.03191.x · Cited by 218 · see citing works

Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies

Pockros, P. J., Guyader, D., Patton, H. M., Tong, M. J., Wright, T., McHutchison, J. G., & Meng, T. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.02.025 · Cited by 218 · see citing works

The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy

Smits, E., Ponsaerts, P., Berneman, Z. N., & Tendeloo, V. F. V. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0097 · Cited by 216 · see citing works

Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma1

Carpentier, A. C., Laigle–Donadey, F., Zohar, S., Capelle, L., Béhin, A., Tibi, A., Martin-Duverneuil, N., Sanson, M., Lacomblez, L., Taillibert, S., et al. (2006) · Neuro-Oncology · doi:10.1215/s1522851705000475 · Cited by 211 · see citing works

Phase II Trial of a Toll-Like Receptor 9–Activating Oligonucleotide in Patients With Metastatic Melanoma

Pashenkov, M. V., Goess, G., Wagner, C., Hörmann, M., Jandl, T., Moser, A., Britten, C. M., Smolle, J., Koller, S. H., Mauch, C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9129 · Cited by 211 · see citing works

A Randomized, Double-blind, Vehicle-Controlled Study to Assess 5% Imiquimod Cream for the Treatment of Multiple Actinic Keratoses

Stockfleth, E. (2002) · Archives of Dermatology · doi:10.1001/archderm.138.11.1498 · Cited by 207 · see citing works

Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study

Carpentier, A. C., Métellus, P., Ursu, R., Zohar, S., Lafitte, F., Barrié, M., Meng, Y., Richard, M., Parizot, C., Laigle–Donadey, F., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop047 · Cited by 204 · see citing works

A Phase I–II Trial of Multiple-Dose Polyriboinosinic-Polyribocytidylic Acid in Patients With Leukemia or Solid Tumors

Robinson, R. A., DeVita, V. T., Levy, H. B., Baron, S., Hubbard, S. P., & Levine, A. S. (1976) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/57.3.599 · Cited by 189 · see citing works

Imiquimod and resiquimod as novel immunomodulators

Dockrell, D. H. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.6.751 · Cited by 186 · see citing works

Induction of Systemic TH1-Like Innate Immunity in Normal Volunteers Following Subcutaneous but Not Intravenous Administration of CPG 7909, a Synthetic B-Class CpG Oligodeoxynucleotide TLR9 Agonist

Krieg, A. Μ., Efler, S. M., Wittpoth, M., Adhami, M. J. A., & Davis, H. L. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200411000-00006 · Cited by 183 · see citing works

Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer

Manegold, C., Gravenor, D. S., Woytowitz, D., Mezger, J. M., Hirsh, V., Albert, G. R., Al-Adhami, M., Readett, D., Krieg, A. Μ., & Leichman, C. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5807 · Cited by 170 · see citing works

First in Human Phase I Trial of 852A, a Novel Systemic Toll-like Receptor 7 Agonist, to Activate Innate Immune Responses in Patients with Advanced Cancer

Dudek, A. Z., Yunis, C., Harrison, L. I., Kumar, S., Hawkinson, R. W., Cooley, S., Vasilakos, J. P., Gorski, K. S., & Miller, J. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1443 · Cited by 169 · see citing works

Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists

Gorski, K. S., Waller, E. L., Bjornton-Severson, J., Hanten, J. A., Riter, C. L., Kieper, W. C., Gorden, K. B., Miller, J. S., Vasilakos, J. P., Tomai, M. A., et al. (2006) · International Immunology · doi:10.1093/intimm/dxl046 · Cited by 158 · see citing works

Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin Lymphoma

Link, B. K., Ballas, Z. K., Weisdorf, D. J., Wooldridge, J. E., Bossler, A., Shannon, M., Rasmussen, W. L., Krieg, A. Μ., & Weiner, G. J. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211304.60126.8f · Cited by 153 · see citing works

Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-α/β–inducible gene expression, without significant toxicity

Friedberg, J. W., Kim, H., McCauley, M., Hessel, E. M., Sims, P. W., Fisher, D. C., Nadler, L. M., Coffman, R. L., & Freedman, A. S. (2004) · Blood · doi:10.1182/blood-2004-06-2156 · Cited by 151 · see citing works

New Generation Vaccine Induces Effective Melanoma-Specific CD8+ T Cells in the Circulation but Not in the Tumor Site

Appay, V., Jandus, C., Voelter, V., Reynard, S., Coupland, S. E., Rimoldi, D., Líénard, D., Guillaume, P., Krieg, A. Μ., Cerottini, J., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.3.1670 · Cited by 150 · see citing works

SALVAGE INTRAVESICAL THERAPY WITH INTERFERON-α2B PLUS LOW DOSE BACILLUS CALMETTE-GUERIN IS EFFECTIVE IN PATIENTS WITH SUPERFICIAL BLADDER CANCER IN WHOM BACILLUS CALMETTE-GUERIN ALONE PREVIOUSLY FAILED

O’Donnell, M. A., KROHN, J., & DeWolf, W. C. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)65757-6 · Cited by 142 · see citing works

Ampligen: A potential toll-like 3 receptor adjuvant for immunotherapy of cancer

Jasani, B., Navabi, H., & Adams, M. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.01.071 · Cited by 140 · see citing works

The low-toxicity versions of LPS, MPL® adjuvant and RC529, are efficient adjuvants for CD4+ T cells

Thompson, B. S., Chilton, P. M., Ward, J. R., et al. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0305172 · Cited by 138 · see citing works

Immunostimulating capacities of stabilized RNA molecules

Scheel, B., Braedel, S., Probst, J., Carralot, J., Wagner, H., Schild, H., Jung, G., Rammensee, H., & Pascolo, S. (2004) · European Journal of Immunology · doi:10.1002/eji.200324198 · Cited by 138 · see citing works

A clinical grade poly I:C-analogue (Ampligen®) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro

Navabi, H., Jasani, B., Reece, A., Clayton, A., Tabi, Z., Donninger, C., Mason, M. D., & Adams, M. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.10.024 · Cited by 133 · see citing works

TLR7/9 Antagonists as Therapeutics for Immune-Mediated Inflammatory Disorders

Karlsson, L., Sun, S., Rao, N. L., Venable, J. D., & Thurmond, R. L. (2007) · Inflammation & Allergy - Drug Targets · doi:10.2174/187152807783334300 · Cited by 133 · see citing works

Role of neutrophils in BCG immunotherapy for bladder cancer

Simons, M. P., O’Donnell, M. A., & Griffith, T. S. (2008) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.11.031 · Cited by 130 · see citing works

A Controlled Clinical Trial with a Specifically Configured RNA Drug, Poly(I). POly(C12U), in Chronic Fatigue Syndrome

Strayer, D. R., Carter, W. A., Brodsky, I., Cheney, P. R., Peterson, D. L., Salvato, P., Thompson, C., Loveless, M. O., Shapiro, D. E., Elsasser, W., et al. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.supplement_1.s88 · Cited by 128 · see citing works

Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma

Green, D. S., Bodman‐Smith, M. D., Dalgleish, A. G., et al. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07664.x · Cited by 128 · see citing works

Phosphorothioate Backbone Modification Modulates Macrophage Activation by CpG DNA

Sester, D. P., Naik, S. H., Beasley, S. J., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.8.4165 · Cited by 122 · see citing works

TLR3 Is Essential for the Induction of Protective Immunity against Punta Toro Virus Infection by the Double-Stranded RNA (dsRNA), Poly(I:C12U), but not Poly(I:C): Differential Recognition of Synthetic dsRNA Molecules

Gowen, B. B., Wong, M., Jung, K., Sanders, A. B., Mitchell, W. M., Alexopoulou, L., Flavell, R. A., & Sidwell, R. W. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.8.5200 · Cited by 116 · see citing works

Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus

McHutchison, J. G., Bacon, B. R., Gordon, S. C., Lawitz, E., Shiffman, M., Afdhal, N. H., Jacobson, I. M., Muir, A. J., Al-Adhami, M., Morris, M. L., et al. (2007) · Hepatology · doi:10.1002/hep.21773 · Cited by 114 · see citing works

An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma

Dummer, R., Hauschild, A., Becker, J. C., Grob, J., Schadendorf, D., Tebbs, V. M., Skalsky, J., Kaehler, K. C., Moosbauer, S., Clark, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1938 · Cited by 114 · see citing works

Improving the Immunogenicity of Pneumococcal Conjugate Vaccine in HIV‐Infected Adults with a Toll‐Like Receptor 9 Agonist Adjuvant: A Randomized, Controlled Trial

Søgaard, O. S., Lohse, N., Harboe, Z. B., Offersen, R., Bukh, A., Davis, H. L., Schønheyder, H. C., & Østergaard, L. J. (2010) · Clinical Infectious Diseases · doi:10.1086/653112 · Cited by 112 · see citing works

Tumor‐reactive CD8+ T‐cell responses after vaccination with NY‐ESO‐1 peptide, CpG 7909 and Montanide® ISA‐51: association with survival

Karbach, J., Gnjatic, S., Bender, A., Neumann, A., Weidmann, E., Yuan, J. D., Ferrara, C. A., Hoffmann, E. W., Old, L. J., Altorki, N. K., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24850 · Cited by 111 · see citing works

Topical Resiquimod 0.01% Gel Decreases Herpes Simplex Virus Type 2 Genital Shedding: A Randomized, Controlled Trial

Mark, K. E., Corey, L., Meng, T., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/513276 · Cited by 111 · see citing works

Imiquimod Enhances the Systemic Immunity Attained by Local Cryosurgery Destruction of Melanoma Lesions

Redondo, P., del Olmo, J., de Cerio, A. L.-D., Inogés, S., Marquina, M., Melero, I., & Bendandi, M. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700777 · Cited by 110 · see citing works

Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery

Thomsen, L. L., Topley, P., Daly, M. G., et al. (2004) · Vaccine · doi:10.1016/j.vaccine.2003.09.052 · Cited by 109 · see citing works

A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily

Savage, P. M., Horton, V. L., Moore, J. L., et al. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.569 · Cited by 109 · see citing works

Immunization With Analog Peptide in Combination With CpG and Montanide Expands Tumor Antigen-specific CD8+ T Cells in Melanoma Patients

Fourcade, J. J., Kudela, P., Filho, P. A. A., Janjic, B. M., Land, S. R., Sander, C., Krieg, A. Μ., Donnenberg, A. D., Shen, H., Kirkwood, J. M., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318183af0b · Cited by 107 · see citing works

Imiquimod for the treatment of genital warts: a quantitative systematic review

Moore, R. A., Edwards, J. E., Hopwood, J., & Hicks, D. A. (2001) · BMC Infectious Diseases · doi:10.1186/1471-2334-1-3 · Cited by 106 · see citing works

Biodistribution and metabolism of internally 3H-labeled oligonucleotides. II. 3',5'-blocked oligonucleotides.

Sands, H., Gorey‐Feret, L. J., HO, S. P., Bao, Y., Cocuzza, A. J., Chidester, D. R., & Hobbs, F. W. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08583-9 · Cited by 99 · see citing works

Oligodeoxynucleotide Modifications Determine the Magnitude of B Cell Stimulation by CpG Motifs

KRIEG, A. M., Matson, S., & Fisher, E. F. (1996) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1996.6.133 · Cited by 96 · see citing works

Viral and Nonviral Uses of Imiquimod: A Review

Gupta, A. K., Cherman, A. M., & Tyring, S. K. (2004) · Journal of Cutaneous Medicine and Surgery · doi:10.1007/s10227-005-0023-5 · Cited by 94 · see citing works

Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection

Thompson, K. A., Strayer, D. R., Salvato, P. D., Thompson, C. E., Klimas, N., Molavi, A., Hamill, A. K., Zheng, Z., Ventura, D., & Carter, W. A. (1996) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01709367 · Cited by 92 · see citing works

Immune Stimulation by a CpG-Containing Oligodeoxynucleotide Is Enhanced When Encapsulated and Delivered in Lipid Particles

Mui, B. L., Raney, S. G., Semple, S. C., & Hope, M. J. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29491-x · Cited by 89 · see citing works

Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells

Spaner, D., Shi, Y., White, D., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2404061 · Cited by 84 · see citing works

Phase II study of a TLR‐9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

Friedberg, J. W., Kelly, J. L., Neuberg, D. S., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07773.x · Cited by 81 · see citing works

Pharmacokinetics of 852A, an Imidazoquinoline Toll‐Like Receptor 7‐Specific Agonist, Following Intravenous, Subcutaneous, and Oral Administrations in Humans

Harrison, L. I., Astry, C. L., Kumar, S., & Yunis, C. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007303766 · Cited by 80 · see citing works

Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms

Harrison, L., Skinner, S. L., Marbury, T., et al. (2004) · Archives of Dermatological Research · doi:10.1007/s00403-004-0465-4 · Cited by 78 · see citing works

Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses

Wu, J. J., Huang, D., & Tyring, S. K. (2004) · Antiviral Research · doi:10.1016/j.antiviral.2004.07.002 · Cited by 77 · see citing works

Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8

Lan, T., Kandimalla, E. R., Yu, D. S., Bhagat, L., Li, Y., Wang, D., Zhu, F., Tang, J. X., Putta, M. R., Cong, Y., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706059104 · Cited by 75 · see citing works

Phase I trial of an oral immunomodulator and interferon inducer in cancer patients.

Witt, P. L., Ritch, P. S., Reding, D. J., et al. (1993) · PubMed · Cited by 73 · see citing works

Randomized, Single-Blind, Placebo-Controlled Studyof Topical Application of the Immune Response ModulatorResiquimod in HealthyAdults

Sauder, D. N., Smith, M. H., Senta-McMillian, T., Soria, I., & Meng, T. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.12.3846-3852.2003 · Cited by 72 · see citing works

Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles

Wilson, K. D., Raney, S. G., Sekirov, L., Chikh, G., deJong, S. D., Cullis, P. R., & Tam, Y. K. (2007) · International Immunopharmacology · doi:10.1016/j.intimp.2007.04.002 · Cited by 70 · see citing works

Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis

Turza, K. C., Dengel, L. T., Harris, R. C., et al. (2009) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2009.01290.x · Cited by 64 · see citing works

Characterization and Modulation of Immune Stimulation by Modified Oligonucleotides

Boggs, R. T., McGraw, K. R., Condon, T. F., Flournoy, S., Villiet, P., Bennett, C. F., & Monia, B. P. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.461 · Cited by 62 · see citing works

Targeting the Effector Site with IFN-αβ-Inducing TLR Ligands Reactivates Tumor-Resident CD8 T Cell Responses to Eradicate Established Solid Tumors

Currie, A. J., van der Most, R., Broomfield, S., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.3.1535 · Cited by 60 · see citing works

Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice

Hamzah, J., Nelson, D. J., Moldenhauer, G., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33201 · Cited by 56 · see citing works

Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)

Ruzsa, Á., Şen, M., Evans, M., Lee, L. W., Hidéghety, K., Rottey, S., Klimak, P., Holečková, P., Fayette, J., Csőszi, T., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0117-2 · Cited by 55 · see citing works

Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod

Spaner, D., Miller, R. L., Mena, J., et al. (2005) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500054426 · Cited by 54 · see citing works

Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma

Green, D. S., Dalgleish, A. G., Belonwu, N., et al. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08709.x · Cited by 50 · see citing works

Targeted Liposomal Delivery of TLR9 Ligands Activates Spontaneous Antitumor Immunity in an Autochthonous Cancer Model

Hamzah, J., Altin, J. G., Herringson, T. P., Parish, C. R., Hämmerling, G. J., O’Donoghue, H., & Ganß, R. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900736 · Cited by 49 · see citing works

The Expression of Toll-like Receptors in Dermatological Diseases and the Therapeutic Effect of Current and Newer Topical Toll-like Receptor Modulators.

Valins, W., Amini, S., & Berman, B. (2010) · PubMed · Cited by 48 · see citing works

Therapeutic effect of intravenous delivery of lipoplexes containing the interferon-β gene and poly I: poly C in a murine lung metastasis model

Sakurai, F., Terada, T., Maruyama, M., et al. (2003) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700617 · Cited by 47 · see citing works

A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia

Spaner, D., Shi, Y., White, D., et al. (2009) · Leukemia · doi:10.1038/leu.2009.195 · Cited by 43 · see citing works

Topical resiquimod promotes priming of CTL to parenteral antigens

Chang, B. A., Cross, J. L., Najar, H. M., & Dutz, J. P. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.07.062 · Cited by 42 · see citing works

Immunostimulatory RNA Oligonucleotides Induce an Effective Antitumoral NK Cell Response through the TLR7

Bourquin, C., Schmidt, L., Lanz, A.-L., Storch, B., Wurzenberger, C., Anz, D., Sandholzer, N., Mocikat, R., Berger, M., Poeck, H., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901594 · Cited by 42 · see citing works

Masked oral prodrugs of toll-like receptor 7 agonists: a new approach for the treatment of infectious disease.

Fletcher, S. P., Steffy, K. R., & Averett, D. R. (2006) · PubMed · Cited by 42 · see citing works

Two‐year interim results from a 5‐year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks

Quirk, C., Gebauer, K., Owens, M., et al. (2006) · Australasian Journal of Dermatology · doi:10.1111/j.1440-0960.2006.00313.x · Cited by 41 · see citing works

Immune System's Toll-like Receptors Have Good Opportunity for Cancer Treatment

Schmidt, C. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj198 · Cited by 41 · see citing works

The pharmacology of endosomal TLR agonists in viral disease

Averett, D. R., Fletcher, S. P., Li, W., et al. (2007) · Biochemical Society Transactions · doi:10.1042/bst0351468 · Cited by 35 · see citing works

Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy

Ondo, A. L., Mings, S. M., Pestak, R. M., et al. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.06.031 · Cited by 33 · see citing works

Update on toll-like receptor-directed therapies for human disease

Tse, K. Y., & Horner, A. A. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.078998 · Cited by 33 · see citing works

Influence of backbone chemistry on immune activation by synthetic oligonucleotides

Pisetsky, D. S., & Reich, C. F. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00294-4 · Cited by 32 · see citing works

Effect of food on the pharmacokinetics and bioavailability of oral imiquimod relative to a subcutaneous dose

Soria, I., Myhre, P. E., Horton, V. L., et al. (2000) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp38476 · Cited by 31 · see citing works

Nonspecific immunotherapy with intratumoral lipopolysaccharide and zymosan A but not GM-CSF leads to an effective anti-tumor response in subcutaneous RG-2 gliomas

Mariani, C. L., Rajon, D. A., Bova, F. J., & Streit, W. J. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-007-9415-2 · Cited by 24 · see citing works

Treatment of Merkel Cell Carcinoma with Radiotherapy and Imiquimod (Aldara): A Case Report

Balducci, M., Bari, B. D., Manfrida, S., et al. (2010) · Tumori Journal · doi:10.1177/030089161009600324 · Cited by 20 · see citing works

Phase I study of TLR9 agonist PF‐3512676 in combination with carboplatin and paclitaxel in patients with advanced non‐small‐cell lung cancer

Yamada, K., Nakao, M., Fukuyama, C., et al. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01361.x · Cited by 19 · see citing works

TLR9‐dependent systemic interferon‐β production by intravenous injection of plasmid DNA/cationic liposome complex in mice

Yoshida, H., Nishikawa, M., Yasuda, S., Mizuno, Y., Toyota, H., Kiyota, T., Takahashi, R., & Takakura, Y. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1348 · Cited by 19 · see citing works

Pharmacokinetic-Pharmacodynamic Modeling of Alpha Interferon Response Induced by a Toll-Like 7 Receptor Agonist in Mice

Benson, N., DeJongh, J., Duckworth, J., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00551-09 · Cited by 16 · see citing works

Mutations in the sodium channel Nav1.7 underlie inherited erythromelalgia

Dib‐Hajj, S. D., Rush, A. M., Cummins, T., et al. (2006) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2006.09.005 · Cited by 16 · see citing works

Successful treatment of primary cutaneous follicle centre lymphoma with topical 5% imiquimod

Stavrakoglou, A., Brown, V. L., & Coutts, I. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07976.x · Cited by 15 · see citing works

Immune response modifiers: Imiquimod and future drugs for modulating the immune response

Tomai, M. A., Miller, R. L., Lipson, K. E., Vasilakos, J. P., & Woulfe, S. L. (2006) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2006.08.003 · Cited by 12 · see citing works

B. C. G. plus recombinant interferon α2b in superficial bladder cancer

Singh, P., Singh, G., Singh, U., et al. (2001) · Indian Journal of Urology · doi:10.4103/0970-1591.21041 · Cited by 6 · see citing works

PD3-1-6: PF-3512676 (CPG 7909), a toll-like receptor 9 agonist-status of development for non-small cell lung cancer (NSCLC)

Readett, D., Denis, L., Krieg, A. Μ., et al. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000283400.75592.3b · Cited by 6 · see citing works

ALDARA (imiquimod cream, 5%)

Abramovits, W., & Gupta, A. K. (2004) · SKINmed Dermatology for the Clinician · doi:10.1111/j.1540-9740.2004.03467.x · Cited by 4 · see citing works

Untitled work

Hoerr, I. (2000) · doi:10.1002/1521-4141(200001)30:1

TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy

Rodell, C. B., Arlauckas, S. P., Cuccarese, M. F., Garris, C. S., Li, R., Ahmed, M. S., Kohler, R. H., Pittet, M. J., & Weissleder, R. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0236-8 · Cited by 1,099 · see citing works

High-capacity poly (2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma

Vinod, N., Hwang, D., Azam, S. H., Van Swearingen, A. E. D., Wayne, E., Fussell, S. C., Sokolsky-Papkov, M., Pecot, C. V., & Kabanov, A. V. (2020) · Science Advances · doi:10.1126/sciadv.aba5542 · Cited by 63 · see citing works

Leveraging Prior Knowledge of Endocrine Immune Regulation in the Therapeutically-relevant Phenotyping of Women with Chronic Fatigue Syndrome

Morris, M. C., Cooney, K. E., Sedghamiz, H., Abreu, M., Collado, F., Balbin, E. G., Craddock, T. J. A., Klimas, N. G., Broderick, G., & Fletcher, M. A. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.03.002 · Cited by 14 · see citing works

The Innate Immune System

Heeg, K. M. (2007) · Neuroimmune biology · doi:10.1016/s1567-7443(07)00205-0

Aspects of the innate and adaptive immune responses to acute infections with BVDV

Brackenbury, L. S., Carr, B. V., & Charleston, B. (2003) · Veterinary Microbiology · doi:10.1016/j.vetmic.2003.09.004 · Cited by 58 · see citing works

Do adaptive immune cells suppress or activate innate immunity?

Zhao, J., Yang, X., Auh, S. L., Kim, K. D., Tang, H., & Fu, Y. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.10.003 · Cited by 40 · see citing works

Earthworm and innate immunity

Liu, Z., & Niu, B. (2008) · Int J Immunol · doi:10.3760/cma.j.issn.1673-4394.2008.04.005

Innate and adaptive immunity

Noakes, P. S., & Michaelis, L. J. (2013) · Elsevier eBooks · doi:10.1533/9780857095749.1.3 · Cited by 12 · see citing works